SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sigfridsson Kalle)
 

Sökning: WFRF:(Sigfridsson Kalle) > Co-administration o...

Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor-the importance of gastrointestinal pH and solubility for the in vivo exposure

Sigfridsson, Kalle, 1964 (författare)
Chalmers tekniska högskola,Chalmers University of Technology
Lundqvist, A. (författare)
AstraZeneca AB
Strimfors, Marie (författare)
AstraZeneca AB
 (creator_code:org_t)
2011-03-21
2011
Engelska.
Ingår i: Drug Development and Industrial Pharmacy. - : Informa UK Limited. - 0363-9045 .- 1520-5762. ; 37:9, s. 1036-1042
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • In Sigfridsson et al. (2011, Drug Dev Ind Pharm, 37: 243-251), there was no difference in plasma concentration of BA99 when administering the drug as nanosuspension or microsuspension and analyzing the blood samples by liquid chromatography-mass spectrometry. This was related to the dissolved amount of drug in the gastric tract, which was high enough to support fast absorption when the drug reached the small intestine. One single physicochemical property (pK(a), about 3 for BA99) abolished the benefit of small particles. These results were further confirmed in the present study, where a proton pump inhibitor, AZD0865, was used to elevate the gastric pH and then drastically decreased the gastric solubility. In this way, BA99 could be considered as a model compound for a neutral substance. By increasing the gastric pH to 5-6 and 8-9, respectively, in rats, the plasma concentrations of BA99, after administering nanosuspensions, were unchanged compared with untreated (i.e. no AZD0865) animals. For microsuspensions of the test compound, on the other hand, the exposure of BA99 was 2- to 3-fold lower than for nanosuspensions at both pHs. Moreover, the blood concentrations of BA99 administered as microsuspension were also 2- to 3-fold lower compared with untreated (no AZD0865) individuals receiving both nanoparticles and microparticles of BA99. Obviously, for neutral compounds, with similar physicochemical properties as the present compound, size reduction will be crucial for increased plasma exposure. For basic compounds, with similar physicochemical properties as the present compound, the crucial step for absorption is the dissolution and solubility in the gastric tract.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

poorly soluble
Dissolution rate
gastric pH
suspension
pharmacokinetic
proton pump inhibitor
nanosuspension

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Sigfridsson, Kal ...
Lundqvist, A.
Strimfors, Marie
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Medicinska och f ...
och Farmakologi och ...
Artiklar i publikationen
Drug Development ...
Av lärosätet
Chalmers tekniska högskola

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy